Zegerid--immediate-release omeprazole.

Abstract

The FDA has approved marketing of Zegerid powder for oral suspension (Santarus), an immediate-release formulation of the proton-pump inhibitor (PPI) omeprazole (Prilosec, and others). All other oral PPIs are delayed-release, enteric-coated formulations designed to prevent degradation of the drug by gastric acid. Each 20- or 40-mg packet of Zegerid contains 1680 mg sodium bicarbonate, which protects the drug from gastric acid degradation. A dose of Zegerid contains 460 mg of sodium, which may be excessive for some patients. Zegerid is the first oral PPI to be approved by the FDA for reduction of risk of upper GI bleeding in critically ill patients. The drug may be useful for patients who are unable to swallow and have nasogastric (NG) tubes in place. Zegerid cost $70.00 for 14 days' treatment, compared to less than $10 for 14 tablets of Prilosec OTC.

• Journal: The Medical letter on drugs and therapeutics (Med Lett Drugs Ther) Vol. 47 Issue 1206 Pg. 29 (Apr 11 2005) ISSN: 0025-732X [Print] United States
• PMID: 15821632 (Publication Type: Journal Article)

Chemical References

• Delayed-Action Preparations
• Omeprazole

Topics

• Delayed-Action Preparations (administration & dosage)
• Humans
• Omeprazole (administration & dosage)